Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1, single-center, randomized, open-label, 3-way crossover study to evaluate the systemic exposure after administration of a tablet formulation of PBT434 in the fed and fasted states compared to a powder in capsule formulation in healthy volunteers

Next Previous
Trial Profile

A phase 1, single-center, randomized, open-label, 3-way crossover study to evaluate the systemic exposure after administration of a tablet formulation of PBT434 in the fed and fasted states compared to a powder in capsule formulation in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATH 434 (Primary) ; ATH 434
  • Indications Multiple system atrophy; Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors Alterity Therapeutics

Most Recent Events

  • 08 Nov 2023 Status changed from recruiting to completed.
  • 22 Nov 2021 Planned number of patients changed from 14 to 42.
  • 22 Nov 2021 Planned End Date changed from 11 Dec 2020 to 10 Dec 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top